Chardan Capital Maintains Buy on Kaleido Biosciences, Lowers Price Target to $3
Chardan Capital analyst Keay Nakae maintains Kaleido Biosciences (NASDAQ:KLDO) with a Buy and lowers the price target from $11 to $3.
Kaleido Halts Upcoming Phase 2 COPD Trial, Piper Sandler Cuts Price Target
Kaleido Biosciences Inc (NASDAQ: KLDO) halted work on a planned phase 2 trial in chronic obstructive pulmonary disease (COPD) and
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's morning trading, 87 companies set new 52-week lows.
